Cinctive Capital Management’s Teva Pharmaceuticals TEVA Stock Holding History

Cinctive Capital Management’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-122,133	Closed	-$3.68M	–	547
2026 Q1	$3.68M	Sell	122,133 -15,247	-11%	-$491K	0.24%	142
2025 Q4	$4.29M	Sell	137,380 -170,151	-55%	-$4.19M	0.23%	123
2025 Q3	$6.21M	Buy	+307,531	New	+$5.4M	0.3%	109
2025 Q1	–	Sell	-117,421	Closed	-$2.59M	–	456
2024 Q4	$2.59M	Sell	117,421 -116,074	-50%	-$2.11M	0.13%	197
2024 Q3	$4.21M	Buy	233,495 +71,164	+44%	+$1.25M	0.23%	146
2024 Q2	$2.64M	Sell	162,331 -223,877	-58%	-$3.45M	0.13%	218
2024 Q1	$5.45M	Buy	386,208 +140,278	+57%	+$1.77M	0.25%	124
2023 Q4	$2.57M	Buy	+245,930	New	+$2.3M	0.17%	159
2020 Q3	–	Sell	-153,486	Closed	-$1.89M	–	370
2020 Q2	$1.89M	Buy	153,486 +54,942	+56%	+$621K	0.22%	191
2020 Q1	$885K	Buy	+98,544	New	+$1.01M	0.2%	158

Other funds holding TEVA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

HIIFS

Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return

Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return

WCM Investment Management Laguna Beach, California $55.2B AUM 57.07% 1-Year Est. Return

Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return

MMH

Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return

MIFH

Migdal Insurance & Financial Holdings Petach Tikva, Israel $15.6B AUM 71.29% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

LIM

Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return

Cinctive Capital Management's TEVA Position: Q2 2026 in Review

Cinctive Capital Management sold out of Teva Pharmaceuticals (TEVA) in Q2 2026, closing a stake of 122,133 shares — an estimated $3.68M sold.

Cinctive Capital Management first reported a position in TEVA in Q1 2020 and held it in 10 quarters. The position peaked at $6.21M in Q3 2025. 672 funds tracked by Wall St. Rank hold TEVA as of Q2 2026.

Cinctive Capital Management reported no remaining Teva Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Cinctive Capital Management sold 122,133 Teva Pharmaceuticals shares in Q2 2026, an estimated $3.68M.
Cinctive Capital Management first reported a position in Teva Pharmaceuticals in Q1 2020 and held it in 10 quarters.
Cinctive Capital Management's Teva Pharmaceuticals position peaked at $6.21M in Q3 2025.
672 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2026.

Based on Cinctive Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.